Clinical Trials Sponsored by CSPC-NBP Pharmaceutical Co., Ltd.

Total 3757 results

CSPC-NBP Pharmaceutical Co., Ltd.

Completed

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

AIS

United States
Conjupro Biotherapeutics, Inc.
CSPC-NBP Pharmaceutical Co., Ltd.

Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Breast Cancer | Peripheral Neuropathy
Capital Medical University
CSPC-NBP Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia

Vascular Dementia

China
Jinling Hospital, China
CSPC-NBP Pharmaceutical Co., Ltd.

Completed

Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting (BPRIAS)

Restenosis

China
Peking Union Medical College Hospital
CSPC-NBP Pharmaceutical Co., Ltd.

Not yet recruiting

A Research of Application of the New Model of Standardized Secondary Prevention of Stroke

Acute Ischemic Stroke
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011

Advanced Breast Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Advanced Biliary Tract Cancer | Extrahepatic Cholangiocarcinoma

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Advanced Pancreatic Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Advanced Breast Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors

Advanced Solid Tumors
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Healthy Subjects

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis

Effects, Drug Side

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

Invasive Aspergillosis | Invasive Candidiasis

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC)
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Recurrent Metastatic Nasopharyngeal Carcinoma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Contrast-induced Acute Kidney Injury

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

Pancreatic Cancer | Advanced Solid Tumor | Gastric Cancer (GC) | Gastroesophageal Junction (GEJ) Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Completed

Bioequivalence of Amphotericin B Liposome for Injection

Bioequivalence

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Withdrawn

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Advanced Solid Tumors

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Completed

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

Bioequivalence

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

3

Subscribe